{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Épilepsie partielle complexe : Questions médicales les plus fréquentes",
"headline": "Épilepsie partielle complexe : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Épilepsie partielle complexe : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-30",
"dateModified": "2025-04-24",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Épilepsie partielle complexe"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Épilepsies partielles",
"url": "https://questionsmedicales.fr/mesh/D004828",
"about": {
"@type": "MedicalCondition",
"name": "Épilepsies partielles",
"code": {
"@type": "MedicalCode",
"code": "D004828",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C10.228.140.490.360"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Épilepsie partielle complexe",
"alternateName": "Epilepsy, Complex Partial",
"code": {
"@type": "MedicalCode",
"code": "D017029",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Xiao-Rong Liu",
"url": "https://questionsmedicales.fr/author/Xiao-Rong%20Liu",
"affiliation": {
"@type": "Organization",
"name": "Institute of Neuroscience, Department of Neurology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China."
}
},
{
"@type": "Person",
"name": "Yong-Hong Yi",
"url": "https://questionsmedicales.fr/author/Yong-Hong%20Yi",
"affiliation": {
"@type": "Organization",
"name": "Institute of Neuroscience, Department of Neurology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China."
}
},
{
"@type": "Person",
"name": "Jie Wang",
"url": "https://questionsmedicales.fr/author/Jie%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Institute of Neuroscience, Department of Neurology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China."
}
},
{
"@type": "Person",
"name": "Wei-Ping Liao",
"url": "https://questionsmedicales.fr/author/Wei-Ping%20Liao",
"affiliation": {
"@type": "Organization",
"name": "Institute of Neuroscience, Department of Neurology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Synthesis of Hydantoin Androgen Receptor Antagonists and Study on Their Antagonistic Activity.",
"datePublished": "2022-09-10",
"url": "https://questionsmedicales.fr/article/36144603",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/molecules27185867"
}
},
{
"@type": "ScholarlyArticle",
"name": "Fibroblast-derived exosomal microRNA regulates NKX3-1 expression in androgen-sensitive, androgen receptor-dependent prostate cancer cells.",
"datePublished": "2023-06-19",
"url": "https://questionsmedicales.fr/article/37334663",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jcb.30435"
}
},
{
"@type": "ScholarlyArticle",
"name": "The androgen receptor-targeted proteolysis targeting chimera and other alternative therapeutic choices in overcoming the resistance to androgen deprivation treatment in prostate cancer.",
"datePublished": "2022-10-06",
"url": "https://questionsmedicales.fr/article/36203075",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12094-022-02957-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Androgen receptor mutations for precision medicine in prostate cancer.",
"datePublished": "2022-08-17",
"url": "https://questionsmedicales.fr/article/35900853",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1530/ERC-22-0140"
}
},
{
"@type": "ScholarlyArticle",
"name": "Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.",
"datePublished": "2022-08-19",
"url": "https://questionsmedicales.fr/article/35995644",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.eururo.2022.08.002"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies du système nerveux",
"item": "https://questionsmedicales.fr/mesh/D009422"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies du système nerveux central",
"item": "https://questionsmedicales.fr/mesh/D002493"
},
{
"@type": "ListItem",
"position": 4,
"name": "Encéphalopathies",
"item": "https://questionsmedicales.fr/mesh/D001927"
},
{
"@type": "ListItem",
"position": 5,
"name": "Épilepsie",
"item": "https://questionsmedicales.fr/mesh/D004827"
},
{
"@type": "ListItem",
"position": 6,
"name": "Épilepsies partielles",
"item": "https://questionsmedicales.fr/mesh/D004828"
},
{
"@type": "ListItem",
"position": 7,
"name": "Épilepsie partielle complexe",
"item": "https://questionsmedicales.fr/mesh/D017029"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Épilepsie partielle complexe - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Épilepsie partielle complexe",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Épilepsie partielle complexe",
"description": "Comment diagnostique-t-on l'épilepsie partielle complexe ?\nQuels tests sont utilisés pour confirmer le diagnostic ?\nLes symptômes peuvent-ils varier d'un patient à l'autre ?\nQuel rôle joue l'historique médical dans le diagnostic ?\nPeut-on diagnostiquer l'épilepsie partielle complexe chez les enfants ?",
"url": "https://questionsmedicales.fr/mesh/D017029?mesh_terms=Androgen+Antagonists&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Épilepsie partielle complexe",
"description": "Quels sont les symptômes typiques des crises ?\nLes crises peuvent-elles affecter la mémoire ?\nComment se manifestent les comportements automatisés ?\nLes crises peuvent-elles être précédées d'aura ?\nLes symptômes peuvent-ils persister après la crise ?",
"url": "https://questionsmedicales.fr/mesh/D017029?mesh_terms=Androgen+Antagonists&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Épilepsie partielle complexe",
"description": "Peut-on prévenir les crises d'épilepsie partielle complexe ?\nQuels sont les déclencheurs courants des crises ?\nL'éducation des proches est-elle importante ?\nLes activités physiques sont-elles sûres ?\nComment gérer le stress pour prévenir les crises ?",
"url": "https://questionsmedicales.fr/mesh/D017029?mesh_terms=Androgen+Antagonists&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Épilepsie partielle complexe",
"description": "Quels médicaments sont couramment prescrits ?\nLa chirurgie est-elle une option de traitement ?\nQuelles sont les alternatives aux médicaments ?\nComment évaluer l'efficacité du traitement ?\nLes changements de mode de vie peuvent-ils aider ?",
"url": "https://questionsmedicales.fr/mesh/D017029?mesh_terms=Androgen+Antagonists&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Épilepsie partielle complexe",
"description": "Quelles sont les complications possibles de l'épilepsie ?\nL'épilepsie peut-elle affecter la vie sociale ?\nY a-t-il un risque accru de dépression ?\nLes crises peuvent-elles entraîner des blessures graves ?\nComment les complications peuvent-elles être gérées ?",
"url": "https://questionsmedicales.fr/mesh/D017029?mesh_terms=Androgen+Antagonists&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Épilepsie partielle complexe",
"description": "Quels sont les facteurs de risque de l'épilepsie partielle complexe ?\nL'âge influence-t-il le risque d'épilepsie ?\nLes maladies neurologiques augmentent-elles le risque ?\nLes facteurs environnementaux jouent-ils un rôle ?\nLe stress peut-il être un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D017029?mesh_terms=Androgen+Antagonists&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on l'épilepsie partielle complexe ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'historique médical, l'EEG et l'imagerie cérébrale."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'EEG et l'IRM sont essentiels pour visualiser l'activité cérébrale et les anomalies."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils varier d'un patient à l'autre ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent différer selon la localisation de l'activité épileptique."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'historique médical dans le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'historique médical aide à identifier les antécédents de crises et les facteurs déclenchants."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer l'épilepsie partielle complexe chez les enfants ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut se manifester chez les enfants, nécessitant une évaluation spécialisée."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes typiques des crises ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des mouvements involontaires, des hallucinations et des troubles de la conscience."
}
},
{
"@type": "Question",
"name": "Les crises peuvent-elles affecter la mémoire ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les crises peuvent entraîner des pertes de mémoire temporaires ou des confusions."
}
},
{
"@type": "Question",
"name": "Comment se manifestent les comportements automatisés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les comportements automatisés incluent des gestes répétitifs sans conscience de l'environnement."
}
},
{
"@type": "Question",
"name": "Les crises peuvent-elles être précédées d'aura ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines personnes ressentent une aura, un signe avant-coureur de la crise."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils persister après la crise ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme la fatigue ou la confusion peuvent persister après la crise."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les crises d'épilepsie partielle complexe ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Bien qu'il soit difficile de prévenir, éviter les déclencheurs connus peut aider."
}
},
{
"@type": "Question",
"name": "Quels sont les déclencheurs courants des crises ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress, le manque de sommeil et l'alcool sont des déclencheurs fréquents."
}
},
{
"@type": "Question",
"name": "L'éducation des proches est-elle importante ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, informer les proches sur les crises et les premiers secours est crucial."
}
},
{
"@type": "Question",
"name": "Les activités physiques sont-elles sûres ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines activités peuvent être sûres, mais il est important de consulter un médecin."
}
},
{
"@type": "Question",
"name": "Comment gérer le stress pour prévenir les crises ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques de relaxation comme la méditation peuvent aider à gérer le stress."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont couramment prescrits ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anticonvulsivants comme la carbamazépine et la lamotrigine sont souvent utilisés."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle une option de traitement ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la chirurgie peut être envisagée si les médicaments ne contrôlent pas les crises."
}
},
{
"@type": "Question",
"name": "Quelles sont les alternatives aux médicaments ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les thérapies comportementales et la stimulation cérébrale peuvent être des options."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité du traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par la fréquence des crises et les effets secondaires des médicaments."
}
},
{
"@type": "Question",
"name": "Les changements de mode de vie peuvent-ils aider ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain, incluant sommeil et gestion du stress, peut aider."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de l'épilepsie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent les blessures lors des crises et des problèmes psychologiques."
}
},
{
"@type": "Question",
"name": "L'épilepsie peut-elle affecter la vie sociale ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des difficultés sociales et des stigmates associés."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de dépression ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes épileptiques présentent un risque plus élevé de dépression et d'anxiété."
}
},
{
"@type": "Question",
"name": "Les crises peuvent-elles entraîner des blessures graves ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les chutes ou les accidents pendant une crise peuvent causer des blessures graves."
}
},
{
"@type": "Question",
"name": "Comment les complications peuvent-elles être gérées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une prise en charge multidisciplinaire est essentielle pour gérer les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de l'épilepsie partielle complexe ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, les traumatismes crâniens et les infections cérébrales sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'épilepsie ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'épilepsie peut survenir à tout âge, mais elle est plus fréquente chez les jeunes enfants et les personnes âgées."
}
},
{
"@type": "Question",
"name": "Les maladies neurologiques augmentent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies comme la sclérose en plaques peuvent augmenter le risque d'épilepsie."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs comme l'exposition à des toxines peuvent contribuer au risque d'épilepsie."
}
},
{
"@type": "Question",
"name": "Le stress peut-il être un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut déclencher des crises chez certaines personnes épileptiques."
}
}
]
}
]
}
Hydroxymethylthiohydantoin, hydroxymethylthiohydantoin, and hydantoin, containing a pyridine group, were synthesized to study their androgen receptor antagonistic activities. Among them, compounds...
Androgen deprivation therapy (ADT) targeting androgen production and androgen receptor (AR) signaling is the primary antihormonal therapy in the treatment of advanced prostate cancer (PCa). However, n...
Androgen receptor (AR) plays a vital role in prostate cancer (PCa), including castration-resistant PCa, by retaining AR signalling. Androgen deprivation treatment (ADT) has been the standard treatment...
Hormonal therapies including androgen deprivation therapy and androgen receptor (AR) pathway inhibitors such as abiraterone and enzalutamide have been widely used to treat advanced prostate cancer. Ho...
Recent randomized controlled trials (RCTs) examined the role of adding androgen receptor signaling inhibitors (ARSIs), including abiraterone acetate (ABI), apalutamide, darolutamide (DAR), and enzalut...
To analyze the oncologic benefit of triplet combination therapies using ARSI + DOC + ADT, and comparing them with available treatment regimens in patients with mHSPC....
Three databases and meetings abstracts were queried in April 2022 for RCTs analyzing patients treated with first-line combination systemic therapy for mHSPC. The primary interests of measure were over...
Overall, 11 RCTs were included for meta-analyses and network meta-analyses (NMAs). We found that the triplet combinations outperformed DOC + ADT in terms of OS (pooled hazard ratio [HR]: 0.74, 95% con...
We found that the triplet combination therapy improves survival endpoints in mHSPC patients compared with currently available doublet treatment regimens. Our findings need to be confirmed in further h...
Our study suggests that triplet therapy with androgen receptor signaling inhibitor, docetaxel, androgen deprivation therapy prolongs survival in patients with metastatic hormone-sensitive prostate can...
By the end of December 2019 new corona virus began to spread from Wuhan, China and caused a worldwide pandemic. COVID-19 deaths and prevalence represented sex discrepant patterns with higher rate of d...
Previously, we reported results from the Phase II BATMAN study (Bipolar Androgen Therapy for Men with Androgen-ablation Naïve prostate cancer). This study (NCT01750398) was designed to evaluate the sa...
Univariate Cox regression was utilized to compare overall survival between Responders who achieved a prostate-specific antigen (PSA) level of <4 ng/ml and Non-Responders who achieved a PSA level of ≥4...
Over median follow-up of 95 months, the median PFS on ADT for the entire cohort was 47.8. Median OS has not been reached (NR). Median OS for Non-Responders is 43 months versus NR (not reached) for res...
The use of BAT as part of first-line hormonal therapy strategy does not induce adversely affect long-term survival or induce any significant long-term adverse sequelae in patients with prostate cancer...
Despite recent advances in the treatments of metastatic castration resistant prostate cancer (mCRPC), patients' prognosis remains suboptimal and novel treatment combinations are under scrutiny. On thi...
A comprehensive search for all published phase III randomized control trials on first line mCRPC that evaluated advanced androgen blockage (COU-AA-302, PREVAIL) or androgen annihilation (ACIS) was con...
Three trials were included involving 3787 patients. Overall, patients receiving androgen annihilation exhibited similar OS compared to advanced androgen blockage: ΔRMST at 36 months of - 0.2 (95%CI: -...
We found no OS benefit for patients with mCRPC treated with androgen annihilation compared to advanced androgen blockage. This might be ascribed to an increased rate of other cause mortality that migh...
There are varied associations that have been identified between the use of androgen deprivation therapy (ADT) and the development of cognitive decline. We highlight the first studies to evaluate chron...
Androgen-deprivation therapy (ADT) historically represented the milestone for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). Recently, combining androgen receptor-targeted agen...
A literature search with no data restriction using Medline/PubMed, the Cochrane Library, and American Society of Clinical Oncology/European Society for Medical Oncology (ASCO/ESMO) Meeting abstracts w...
Five randomized clinical trials fulfilled the prespecified inclusion criteria. The triplet significantly improved OS (fixed-effect, HR = 0.74; P < 0.00001) and PFS (fixed-effect; HR = 0.50 for clinica...
Emerging evidence supports the combination of an ARTA plus docetaxel and ADT in mHSPC patients. Given the availability of several strategies in this setting, clinical characteristics and drug safety p...